These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

837 related articles for article (PubMed ID: 7522959)

  • 21. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H; Snoek R; Ghaidi F; Cox ME; Rennie PS
    Cancer Res; 2006 Nov; 66(21):10613-20. PubMed ID: 17079486
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR; Lee E; Thompson TA; Basu HS; Ripple MO; Ariazi EA; Wilding G
    Prostate; 2005 May; 63(2):155-68. PubMed ID: 15486991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A; Scullin P; Maxwell PJ; Wilson C; Pettigrew J; Gallagher R; O'Sullivan JM; Johnston PG; Waugh DJ
    Carcinogenesis; 2008 Jun; 29(6):1148-56. PubMed ID: 18487223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
    Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
    Plymate SR; Tennant MK; Culp SH; Woodke L; Marcelli M; Colman I; Nelson PS; Carroll JM; Roberts CT; Ware JL
    Prostate; 2004 Nov; 61(3):276-90. PubMed ID: 15368471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
    Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
    Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
    Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
    Lim JT; Piazza GA; Pamukcu R; Thompson WJ; Weinstein IB
    Clin Cancer Res; 2003 Oct; 9(13):4972-82. PubMed ID: 14581372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
    Attardi BJ; Burgenson J; Hild SA; Reel JR
    Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment and characterization of an androgen receptor-dependent, androgen-independent human prostate cancer cell line, LNCaP-CS10.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Ishii N; Aoki Y
    Prostate; 2010 Apr; 70(5):457-66. PubMed ID: 19902465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
    Chen F; Knecht K; Leu C; Rutledge SJ; Scafonas A; Gambone C; Vogel R; Zhang H; Kasparcova V; Bai C; Harada S; Schmidt A; Reszka A; Freedman L
    J Steroid Biochem Mol Biol; 2004 Aug; 91(4-5):247-57. PubMed ID: 15336702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
    Quéro L; Giocanti N; Hennequin C; Favaudon V
    Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
    Yan J; Xie B; Capodice JL; Katz AE
    Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells.
    Culig Z; Hobisch A; Hittmair A; Cronauer MV; Radmayr C; Zhang J; Bartsch G; Klocker H
    Prostate; 1997 Jul; 32(2):106-14. PubMed ID: 9215398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
    Liu S; Yuan Y; Okumura Y; Shinkai N; Yamauchi H
    Biochem Biophys Res Commun; 2010 Apr; 394(2):297-302. PubMed ID: 20206136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.